10-Q: ZyVersa Therapeutics Q1 2026 Financial Update

ZyVersa Therapeutics reports a net loss of $1.8 million for Q1 2026, with significant cash burn and ongoing need for financing.

Summary

• ZyVersa Therapeutics reported a net loss of $1.8 million for the first quarter ended March 31, 2026, compared to a net loss of $2.3 million for the same period in 2025.
• Total operating expenses decreased by 39.2% to $1.3 million in Q1 2026 from $2.1 million in Q1 2025, primarily due to a significant reduction in research and development expenses.
• Research and development expenses decreased by 77.6% to $58,000 in Q1 2026 from $259,000 in Q1 2025, attributed to lower payroll costs following the Chief Medical Officer's retirement and a pause in the VAR 200 study.
• General and administrative expenses decreased by 33.9% to $1.2 million in Q1 2026 from $1.9 million in Q1 2025, mainly due to reduced professional fees and marketing expenses.
• The company had cash of $0.3 million as of March 31, 2026, and a working capital deficiency of $14.1 million, raising substantial doubt about its ability to continue as a going concern.
• Financing activities provided $1.0 million in Q1 2026 from a convertible note and warrants, compared to $1.9 million in Q1 2025 from a private placement of warrants.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the substantial doubt about the company's going concern status, significant working capital deficit, and reliance on future financing, despite some cost-saving measures.

Positives

• Significant reduction in operating expenses, particularly in research and development (77.6% decrease) and general and administrative (33.9% decrease) for Q1 2026 compared to Q1 2025.
• The company secured $1.0 million in financing through a convertible note and warrants in Q1 2026.
• Disclosure controls and procedures were deemed effective by the CEO and CFO.

Negatives

• The company incurred a net loss of $1.8 million in Q1 2026.
• As of March 31, 2026, the company had only $0.3 million in cash and a working capital deficiency of $14.1 million.
• Substantial doubt exists regarding the company's ability to continue as a going concern for at least one year.
• The company has not generated any revenue to date and expects to continue incurring operating losses.
• A significant increase in other expenses, primarily due to a $344,000 fair value option loss on convertible notes.

Risks

• The company's ability to continue as a going concern is in doubt due to its lack of revenue, accumulated deficit, and limited cash reserves.
• Failure to secure additional financing on acceptable terms could negatively impact the company's financial condition and ability to pursue its business strategy.
• The company may never achieve profitability.
• The development of product candidates is highly uncertain, with risks associated with clinical trial duration, patient enrollment, regulatory approvals, and efficacy/safety profiles.
• The company is reliant on a single vendor for 56% of its accounts payable related to research and development.
• Disputed vendor invoices totaling $1,068,180 for retroactive interest and unsupported charges remain unrecorded as a liability but are being accrued for interest from July 1, 2024.
• Additional vendor invoices totaling $117,525 for work completed between 2019 and 2020 are being disputed.

Future Outlook

The company expects to continue incurring significant expenses for research and development, regulatory submissions, manufacturing, personnel hiring, and intellectual property protection. Additional financing through equity or debt is required to support ongoing operations, and there is no assurance that such funds will be available on acceptable terms or at all. The company may never achieve profitability.

Management Comments

• Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all.
• There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations.
• Management does not expect that its disclosure controls and procedures or its internal control over financial reporting will prevent or detect all errors and fraud.
• Management believes that current cash is only sufficient to fund operations and capital requirements on a month-to-month basis.

Industry Context

StockSavvy.ai notes that ZyVersa Therapeutics operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, where significant investment is required for drug development with a high degree of inherent risk and long development timelines. The company's focus on renal and inflammatory diseases addresses areas with unmet medical needs, but success is contingent on navigating complex regulatory pathways and securing substantial funding.

Comparison to Industry Standards

• The company's net loss of $1.8 million for the quarter is within the expected range for clinical-stage biopharmaceutical companies that are pre-revenue and investing heavily in R&D.
• The significant reduction in R&D expenses (77.6%) in Q1 2026 compared to Q1 2025, while potentially a cost-saving measure, could also indicate a slowdown in development progress or a strategic shift, which warrants close monitoring.
• The company's cash burn rate of approximately $0.8 million per month in operating activities for Q1 2026, coupled with a cash balance of $0.3 million, highlights a critical need for immediate and substantial financing, a common challenge for companies at this stage.
• The substantial accumulated deficit of $139.4 million is typical for biopharmaceutical companies that have been in development for several years without generating revenue.

Legal Proceedings

• The company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business.

Stakeholder Impact

• Shareholders face dilution risk if additional equity is issued for capital raises.
• Creditors and suppliers may face increased risk due to the company's precarious financial situation and potential inability to meet obligations.
• Employees may face uncertainty regarding job security given the going concern issues and need for financing.

Next Steps

• Continue development of VAR 200 and IC 100.
• Prepare and file regulatory submissions.
• Begin manufacturing product candidates for clinical trials.
• Hire additional research and development, finance, and general and administrative personnel.
• Protect and defend intellectual property.
• Meet the requirements of being a public company.
• Seek additional financing through equity or debt.

Key Dates

Recommendation

The company's severe liquidity constraints, substantial doubt about its ability to continue as a going concern, and lack of revenue generation present significant risks. The need for substantial future financing, with no guarantee of success, coupled with a significant increase in fair value losses on convertible notes, makes the investment highly speculative and warrants a sell recommendation.

Keywords

ZyVersa Therapeutics, Form 10-Q, Quarterly Report, Biopharmaceutical, Clinical Stage, Renal Disease, Inflammatory Disease, VAR 200, IC 100, FSGS, Net Loss, Going Concern, Financing, Convertible Notes, Warrants